|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1. Baseline characteristics of the study population according to incremental hs-cTnT groups** | | | | | | | | | | | | | | | | | | | | | | |
|  | |  | | |  | High-Sensitivity Cardiac Troponin T (ng/L) | | | | | | | | | | | | | | |  |  |
|  | | Total | | |  | ≤3  (n=1694) | | |  | 4-9  (n=1085) | | |  | 10-19  (n=614) | | |  | 20-30  (n=175) | | |  | Ptrend\*\* |
| Variable | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hs-cTnT (ng/L) | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Women | 1033 |  | 3 (3-6) |  | 634 |  | NA |  | 258 |  | 6 (5-7) |  | 104 |  | 12 (11-15) |  | 37 |  | 23 (22-27) |  | - |
|  | Men | 2535 |  | 5 (3-10) |  | 1060 |  | NA |  | 827 |  | 6 (5-8) |  | 510 |  | 13 (11-16) |  | 138 |  | 24 (21-27) |  | - |
| Age (years) | | 3568 |  | 61 (54-69) |  | 1694 |  | 57 (51-64) |  | 1085 |  | 64 (57-70) |  | 614 |  | 67 (60-74) |  | 175 |  | 70(59-76) |  | <0.000001 |
| Women | | 3568 |  | 1033 (30.0%) |  | 1694 |  | 634 (37.4%) |  | 1085 |  | 258 (23.8%) |  | 614 |  | 104 (16.9%) |  | 175 |  | 37 (21.1%) |  | <0.000001 |
| BMI (kg/m2) | | 3565 |  | 26 (24-28) |  | 1693 |  | 26 (24-28) |  | 1083 |  | 26 (24-29) |  | 614 |  | 26 (24-29) |  | 175 |  | 26 (24-29) |  | 0.11 |
| Previous AMI | | 3568 |  | 1408 (39.5%) |  | 1694 |  | 507 (29.9%) |  | 1085 |  | 461 (42.5%) |  | 614 |  | 337 (54.9%) |  | 175 |  | 103 (58.9%) |  | <0.000001 |
| Previous PCI | | 3568 |  | 690 (19.3%) |  | 1694 |  | 347 (20.5%) |  | 1085 |  | 195 (18.0%) |  | 614 |  | 124 (20.2%) |  | 175 |  | 24 (13.7%) |  | 0.18 |
| Previous CABG | | 3568 |  | 388 (10.9%) |  | 1694 |  | 146 (8.62%) |  | 1085 |  | 133 (12.3%) |  | 614 |  | 86 (14.0%) |  | 175 |  | 23 (13.1%) |  | 0.92 |
| Previous PAD | | 3568 |  | 305 (8.5%) |  | 1694 |  | 103 (6.08%) |  | 1085 |  | 99 (9.12%) |  | 614 |  | 74 (12.1%) |  | 175 |  | 29 (16.6%) |  | 0.0005 |
| Left ventricular ejection fraction (%) | | 3568 |  | 67 (60-70) |  | 1694 |  | 70 (60-70) |  | 1085 |  | 66 (60-70) |  | 614 |  | 61 (55-70) |  | 175 |  | 60 (50-70) |  | <0.000001 |
| Diabetes mellitus | | 3568 |  | 392 (11.0%) |  | 1694 |  | 130 (7.67%) |  | 1085 |  | 120 (11.1%) |  | 614 |  | 108 (17.6%) |  | 175 |  | 34 (19.4%) |  | <0.000001 |
| Hypertension | | 3568 |  | 1623 (45.5%) |  | 1694 |  | 684 (40.4%) |  | 1085 |  | 511 (47.1%) |  | 614 |  | 324 (52.8%) |  | 175 |  | 104 (59.4%) |  | 0.000002 |
| Current smoker | | 3564 |  | 968 (27.1%) |  | 1691 |  | 507 (30.0%) |  | 1085 |  | 294 (27.1%) |  | 613 |  | 173 (28.2%) |  | 175 |  | 48 (27.4%) |  | <0.000001 |
| Blood pressure | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Systolic (mmHg) | 3522 |  | 140  (126–154) |  | 1676 |  | 138  (125–150) |  | 1064 |  | 141  (129-156) |  | 608 |  | 140  (129-158) |  | 174 |  | 140  (130-159) |  | 0.57 |
|  | Diastolic (mmHg) | 3520 |  | 80  (75–88) |  | 1676 |  | 80  (75-87) |  | 1062 |  | 80  (75-89) |  | 608 |  | 80  (75-90) |  | 174 |  | 80  (74-89) |  | 1.00 |
| eGFR | | 3562 |  | 91  (80-100) |  | 1693 |  | 96  (88-103) |  | 1083 |  | 89  (78-97) |  | 611 |  | 82  (69-94) |  | 175 |  | 80  (64 – 91) |  | <0.000001 |
| Serum lipid parameters | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Total cholesterol (mmol/L) | 3566 |  | 4.9  (4.3-5.7) |  | 1693 |  | 5.0  (4.3-5.8) |  | 1085 |  | 4.9  (4.3-5.7) |  | 614 |  | 4.8  (4.1-5.6) |  | 174 |  | 4.9  (4.2-5.7) |  | 0.02 |
|  | LDL cholesterol (mmol/L) | 3565 |  | 2.9  (2.4-3.7) |  | 1693 |  | 3.0  (2.4-3.7) |  | 1085 |  | 2.9  (2.4-3.7) |  | 613 |  | 2.8  (2.3-3.6) |  | 174 |  | 2.8  (2.4-3.6) |  | 0.01 |
|  | HDL cholesterol (mmol/L) | 3567 |  | 1.2  (1.0-1.5) |  | 1694 |  | 1.2  (1.1-1.5) |  | 1085 |  | 1.2  (1.0-1.5) |  | 614 |  | 1.2  (1.0–1.5) |  | 174 |  | 1.2  (1.0-1.4) |  | <0.00001 |
|  | Triglycerides (mmol/L) | 3564 |  | 1.5  (1.1-2.2) |  | 1693 |  | 1.5  (1.1-2.2) |  | 1084 |  | 1.5  (1.1-2.2) |  | 613 |  | 1.5  (1.1-2.1) |  | 174 |  | 1.6  (1.1-2.2) |  | 0.003 |
|  | Serum apo A1 (g/L) | 3567 |  | 1.3  (1.1-1.5) |  | 1694 |  | 1.3  (1.2-1.5) |  | 1085 |  | 1.3  (1.2-1.5) |  | 613 |  | 1.3  (1.1-1.5) |  | 175 |  | 1.3  (1.1-1.4) |  | 0.004 |
|  | Serum B100  (g/L) | 3568 |  | 0.9  (0.7-1.0) |  | 1694 |  | 0.9  (0.7-1.0) |  | 1085 |  | 0.9  (0.8-1.1) |  | 614 |  | 0.9  (0.7-1.0) |  | 175 |  | 0.9  (0.7-1.1) |  | 0.08 |
| Medications at discharge | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Aspirin | 3568 |  | 2950 (82.7%) |  | 1694 |  | 1409(83.2%) |  | 1085 |  | 900 (82.9%) |  | 614 |  | 502 (81.8%) |  | 175 |  | 139 (79.4%) |  | 0.14 |
|  | Beta blocker | 3568 |  | 2614 (73.3%) |  | 1694 |  | 1199(70.8%) |  | 1085 |  | 813 (74.9%) |  | 614 |  | 471 (76.7%) |  | 175 |  | 131 (74.9%) |  | 0.07 |
|  | ACE-inhibitor or ARB | 3568 |  | 1057 (29.6%) |  | 1694 |  | 371 (21.9%) |  | 1085 |  | 340 (31.3%) |  | 614 |  | 267 (43.5%) |  | 175 |  | 79 (45.1%) |  | <0.000001 |
|  | Statin | 3568 |  | 2611 (73.2%) |  | 1694 |  | 1210(71.4%) |  | 1085 |  | 812 (74.8%) |  | 614 |  | 465 (75.7%) |  | 175 |  | 124 (70.9%) |  | 0.40 |
|  | CCB | 3568 |  | 872 (20.9%) |  | 1694 |  | 312 (18.4%) |  | 1085 |  | 265 (24.4%) |  | 614 |  | 155 (25.2%) |  | 175 |  | 46 (26.3%) |  | 0.50 |
|  | Loop diuretic | 3568 |  | 290 (8.1%) |  | 1694 |  | 74 (4.4%) |  | 1085 |  | 69 (6.4%) |  | 614 |  | 93 (15.1%) |  | 175 |  | 54 (30.9%) |  | <0.000001 |
| \* Number of patients with valid measurements | | | | | | | | | | | | | | | | | | | | | | |
| \*\* Adjusted for age and gender | | | | | | | | | | | | | | | | | | | | | | |
| BMI = Body mass index; AMI = acute myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; PAD = peripheral artery disease; eGFR = estimated glomerular filtration rate; LDL = low-density lipoprotein; HDL = high-density lipoprotein; ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker | | | | | | | | | | | | | | | | | | | | | | |